- HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call
- HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
- HLS Therapeutics Announces Fiscal 2023 Financial Results
- HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call
- HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan
More ▼
Key statistics
On Friday, HLS Therapeutics Inc (HLS:TOR) closed at 4.75, 42.22% above the 52 week low of 3.34 set on Nov 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.70 |
---|---|
High | 4.75 |
Low | 4.70 |
Bid | 4.42 |
Offer | 4.78 |
Previous close | 4.65 |
Average volume | 2.88k |
---|---|
Shares outstanding | 31.89m |
Free float | 31.73m |
P/E (TTM) | -- |
Market cap | 151.46m CAD |
EPS (TTM) | -1.17 CAD |
Annual div (ADY) | -- |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | Apr 27 2023 |
Div pay-date | Jun 15 2023 |
Data delayed at least 15 minutes, as of May 03 2024 19:06 BST.
More ▼